In a French cohort of 189,289 IBD patients, the incidence rate of this neoplasm was higher in patients treated with anti-TNF monotherapy or combo-therapy when compared with those unexposed (aHR = 2.41, p < 0.01; and aHR = 6.11, p < 0.01, respectively) [59]. The gene discussed is TNF; the disease is inflammatory bowel disease.